Cyclacel Pharmaceuticals Inc (CYCC)vsInsmed Inc (INSM)
CYCC
Cyclacel Pharmaceuticals Inc
$6.37
0.00%
HEALTHCARE · Cap: $14.25M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 6064130% more annual revenue ($606.42M vs $10,000). CYCC leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CYCC
Avoid15
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+100.0%
Fair Value
$48439.80
Current Price
$6.37
$48433.44 discount
Intrinsic value data unavailable for INSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -2.8% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CYCC
The strongest argument for CYCC centers on Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CYCC
The primary concerns for CYCC are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CYCC profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
CYCC generates stronger free cash flow (-1,056), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 15/100). CYCC offers better value entry with a 100.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cyclacel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?